This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Experts
Simani Price
Associate Vice President
Contact
SimaniPrice@westat.comOverview
Simani Price, PhD, an Associate Vice President for Public Health, directs multimethod evaluations, national surveys, and formative research that informs measures development, health interventions, and messaging. Her research and evaluation studies include public health topics such as birth defects, chronic disease, emergency preparedness, environmental health, immunization, tobacco, vaccine safety surveillance, and Zika.
Education
- PhD, Applied Social Psychology (minor in Marketing Research), Virginia Polytechnic Institute and State University
- MS, Experimental Psychology, Virginia Polytechnic Institute and State University
- MPA, Public Policy/Public Administration, University of Kentucky
- BA, Psychology and Political Science (Honors Program), University of Kentucky
-
Evidence of novel susceptibility variants for prostate cancer and a multiancestry polygenic risk score associated with aggressive disease in men of African ancestry
European Urology
January 2023
F. Chen, R.K. Madduri, A.A. Rodriguez, B.F. Darst, A. Chou, X. Sheng, A. Wang, et al.
DOILink for: Evidence of novel susceptibility variants for prostate cancer and a multiancestry polygenic risk score associated with aggressive disease in men of African ancestry -
Influence of data disclosures on physician decisions about off-label uses: Findings from a qualitative study
23,
BMC Primary Care
January 2022
M.C. Chansky, Simani Price, K.J. Aikin, A.C. O'Donoghue
DOILink for: Influence of data disclosures on physician decisions about off-label uses: Findings from a qualitative study -
Effect of repeat vaccination on immunogenicity of quadrivalent cell-culture and recombinant influenza vaccines among healthcare personnel aged 18–64 Years: A randomized, open-label trial
Clinical Infectious Diseases
January 2022
M. Gaglani, S.S. Kim, A.L. Naleway, M.Z. Levine, L. Edwards, K. Murthy, K. Dunnigan, et al.
DOILink for: Effect of repeat vaccination on immunogenicity of quadrivalent cell-culture and recombinant influenza vaccines among healthcare personnel aged 18–64 Years: A randomized, open-label trial